UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial

 1520398623 
1599155181
UAB's Facebook Page

The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.

During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.

“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”

Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.

But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.

“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”

Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.

“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”

She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.

“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”

Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.

Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.

UAB's Dr. Jeanne Marrazzo gives an update about COVID-19 as we head into Labor Day weekend.

Posted by WBHM on Thursday, September 3, 2020

More Coronavirus Coverage

ADPH Plans Mobile Vaccination Clinics For Black Belt Region

State health officials hope to administer more vaccines to residents of rural areas.

Ivey Extends Face Mask Order But Not For Long

Gov. Ivey leaves face mask order alone for now, but says it will end April 9.

UAB And JeffCo To Expand Vaccine Outreach In Underrepresented Communities

As of Wednesday, UAB had administered roughly 80,000 vaccine doses, but Black residents remain disproportionately underrepresented.

Alabama’s COVID-19 Death Count Nears 10,000 Mark

Within about a year, the state has lost almost 10,000 Alabamians to COVID-19.

UAB Officials Hopeful Johnson & Johnson Vaccine Could Accelerate Rollout

UAB health experts say when it comes to vaccine variety, more is better. The Johnson & Johnson vaccine is the latest to win approval from the federal government.

Alabama’s COVID Vaccination Rate Increases

Federal programs have helped increase the number of Alabamians getting vaccinated in recent weeks.

More Coronavirus Coverage